DKF-313
As of the edition of 20 October 2026, DKF-313 is a drug known only by a code name: in active development; acts on PDE5A, SRD5A1 and SRD5A2 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Code name only
- Registered trials
- 2, 0 stopped early
- Disease areas
- Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Dongkook Pharmaceutical | Lead sponsor of trials | 2015 to now |